Neuroreceptor imaging in psychiatric disorders
- 1 November 2002
- journal article
- review article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 16 (7) , 437-446
- https://doi.org/10.1007/bf02988639
Abstract
Molecular imaging, the study of receptors, transporters and enzymes, as well as other cellular processes, has grown in recent years to be one of the most active neuroimaging areas. The application of single photon emission tomography (SPECT) and positron emission tomography (PET) techniques to the study of psychiatric illness has lead to increased understanding of disease processes as well as validated,in vivo, theories of illness etiology. Within the field of psychiatry these techniques have been applied most widely to the study of schizophrenia. Studies within schizophrenia are largely limited to either the dopamine or serotonin system. This is due in large part to the availability of suitable radiotracers as well as the current theories on the etiology of the illness. Two basic study designs are used when studying schizophrenia using molecular imaging and make up the majority of studies reviewed in this manuscript. The first type, termed “clinical studies,” compares the findings from PET and SPECT studies in those with schizophrenia to normal controls in an attempt to understand the pathophysiology of the illness. The second study design, termed “occupancy studies,” uses these techniques to enhance the understanding of the mechanism of action of the medications used in treating this illness. This review will focus on the findings of molecular imaging studies in schizophrenia, focusing, for the most part, on the serotonin and dopamine systems. Emphasis will be placed on how these findings and techniques are currently being used to inform the development of novel treatments for schizophrenia.Keywords
This publication has 83 references indexed in Scilit:
- Facilitation of dopaminergic neural transmission does not affect [11C]SCH23390 binding to the striatal D1 dopamine receptors, but the facilitation enhances phosphodiesterase type‐IV activity through D1 receptors: PET studies in the conscious monkey brainSynapse, 2001
- (−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptorsNuclear Medicine and Biology, 2000
- Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomographyLife Sciences, 2000
- D1 receptors in prefrontal cells and circuitsBrain Research Reviews, 2000
- The Role of Serotonin in Antipsychotic Drug ActionNeuropsychopharmacology, 1999
- 505: D1-Dopamine receptors in schizophrenia examined by petSchizophrenia Research, 1997
- Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracerNuclear Medicine and Biology, 1995
- D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic PatientsThe British Journal of Psychiatry, 1994
- [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with petLife Sciences, 1993
- DOPAMINE D2 RECEPTORS IN SCHIZOPHRENIA STUDIED IN VIVOThe Lancet, 1986